Oncology & Cancer

A group led by the Department of Neurosurgery, Brain Research Institute, Niigata University, has succeeded in the diagnosis of leptomeningeal disease in diffuse midline gliomas by detecting H3K27M-mutant droplets from circulating tumor DNA of cerebrospinal fluid taken from these patients.

A person’s lifetime risk for cancer may begin before they are even born, reports a paradigm-shifting study by Van Andel Institute scientists.

Glycolysis is a central metabolic pathway by which cells obtain energy from sugar. Cancer cells in particular have long been thought to depend on the energy obtained through glycolysis, a phenomenon known as the Warburg effect. Today we know that cancer cells can use energy sources more flexibly than previously thought. Even when glycolysis is blocked, they survive by obtaining their energy through the respiratory chain.

UK oncology researchers have come together to write the first-ever national thought leadership strategy report into cancer vaccine advances and the opportunities these present for those affected by cancer. The strategy report has been published in the journal Cambridge Prisms: Precision Medicine.

Hadron therapy is a state-of-the-art radiotherapy technique that uses proton or ion beams to target tumoral cells, while sparing surrounding healthy tissues from unwanted radiation. To achieve best results, it requires complex systems, called gantries, that rotate around the patient, carrying magnets that guide the hadron beams precisely onto tumors. Unfortunately, these are usually massive and costly machines, which represent a limiting factor for the spread of the treatment technique.

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

A new international clinical trial led by the National Cancer Center Singapore is reporting that three years of aspirin following standard adjuvant therapy for high-risk Dukes’ B and C colorectal cancer did not yield a significant advantage in preventing disease recurrence.

Oxford University researchers have unveiled a new blood test, powered by machine learning, that shows promise in detecting multiple types of cancer in their earliest stages, when the disease is hardest to detect.

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center have identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts (chimeric antigen receptor-T cells) to fight cancer. This finding may have a significant impact on improving the production of CAR-T cells for clinical use.

With cancer still rising in the U.S. Latino population, leaders at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and national cancer experts have published an online book with innovative recommendations to reduce Latino cancer.